Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

Redefining Treatment Paradigms in First-line Advanced Non-Small-Cell Lung Cancer.

Heigener DF, Kerr KM, Laing GM, Mok TSK, Moiseyenko FV, Reck M.

Clin Cancer Res. 2019 Aug 15;25(16):4881-4887. doi: 10.1158/1078-0432.CCR-18-1894. Epub 2019 Mar 25. Review.

PMID:
30910855
2.

Crizotinib.

Heigener DF, Reck M.

Recent Results Cancer Res. 2018;211:57-65. doi: 10.1007/978-3-319-91442-8_4. Review.

PMID:
30069759
3.

Impact of PD-L1 Expression in EGFR-Positive NSCLC? The Answer Remains the Same….

Heigener DF, Reck M.

J Thorac Oncol. 2018 Aug;13(8):1060-1061. doi: 10.1016/j.jtho.2018.06.001. Epub 2018 Jul 2. No abstract available.

4.

Advanced non-small cell lung cancer: the role of PD-L1 inhibitors.

Heigener DF, Reck M.

J Thorac Dis. 2018 May;10(Suppl 13):S1468-S1473. doi: 10.21037/jtd.2018.01.112. Review.

5.

Lung cancer in 2017: Giant steps and stumbling blocks.

Heigener DF, Reck M.

Nat Rev Clin Oncol. 2018 Feb;15(2):71-72. doi: 10.1038/nrclinonc.2017.178. Epub 2017 Nov 21. Review. No abstract available.

PMID:
29158589
6.

[Lung cancer : What has been confirmed in therapy?]

Heigener DF, Reck M.

Internist (Berl). 2017 Dec;58(12):1258-1263. doi: 10.1007/s00108-017-0339-4. Review. German.

PMID:
29043377
7.

Efficacy and Safety of Nintedanib Plus Docetaxel in Patients with Advanced Lung Adenocarcinoma: Complementary and Exploratory Analyses of the Phase III LUME-Lung 1 Study.

Gottfried M, Bennouna J, Bondarenko I, Douillard JY, Heigener DF, Krzakowski M, Mellemgaard A, Novello S, Orlov S, Summers Y, von Pawel J, Stöhr J, Kaiser R, Reck M.

Target Oncol. 2017 Aug;12(4):475-485. doi: 10.1007/s11523-017-0517-2.

PMID:
28702806
8.

[Chemotherapy in the Elderly with Non-Small Cell Lung Cancer: A Non-Interventional, Prospective, Multicentric Observational Study].

Heigener DF, Hoeffken G, Wuerflein D, Feurer M, Rittmeyer A, Huber RM, Pietsch M, Ring A, Deppermann KM.

Dtsch Med Wochenschr. 2017 Feb;142(4):e21-e27. doi: 10.1055/s-0042-121785. Epub 2017 Feb 24. German.

PMID:
28235221
9.

PD-1 Axis Inhibition in EGFR Positives: A Blunt Sword?

Heigener DF, Reck M.

J Thorac Oncol. 2017 Feb;12(2):171-172. doi: 10.1016/j.jtho.2016.12.013. No abstract available.

10.

Second-Line Treatment Selection in Patients With Non-Small-Cell Lung Cancer of Adenocarcinoma Histology: Findings From a European Survey of Treating Physicians.

Girard N, Corral J, Cortinovis D, Heigener DF.

Clin Lung Cancer. 2017 Mar;18(2):e89-e97. doi: 10.1016/j.cllc.2016.10.004. Epub 2016 Oct 26.

PMID:
27865625
11.

[Targeted therapy and precision medicine : More than just words in the treatment of lung cancer].

Heigener DF, Horn M, Reck M.

Internist (Berl). 2016 Dec;57(12):1243-1249. doi: 10.1007/s00108-016-0121-z. German.

PMID:
27587193
12.

Immunotherapy: the third wave in lung cancer treatment.

Heigener DF, Reck M.

Lancet Respir Med. 2015 Dec;3(12):923-4. doi: 10.1016/S2213-2600(15)00429-4. No abstract available.

PMID:
26679022
13.

Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors.

Heigener DF, Schumann C, Sebastian M, Sadjadian P, Stehle I, Märten A, Lüers A, Griesinger F, Scheffler M; Afatinib Compassionate Use Consortium (ACUC).

Oncologist. 2015 Oct;20(10):1167-74. doi: 10.1634/theoncologist.2015-0073. Epub 2015 Sep 9.

14.

Targeting of MEK in lung cancer therapeutics.

Heigener DF, Gandara DR, Reck M.

Lancet Respir Med. 2015 Apr;3(4):319-27. doi: 10.1016/S2213-2600(15)00026-0. Epub 2015 Mar 20. Review.

PMID:
25801412
15.

[Non-small cell lung cancer: news from immunotherapy].

Reinmuth N, Heigener DF, Reck M.

Dtsch Med Wochenschr. 2015 Mar;140(5):329-33. doi: 10.1055/s-0041-100763. Epub 2015 Mar 3. Review. German.

PMID:
25734674
16.

Weekly and every 2 weeks cetuximab maintenance therapy after platinum-based chemotherapy plus cetuximab as first-line treatment for non-small cell lung cancer: randomized non-comparative phase IIIb NEXT trial.

Heigener DF, Pereira JR, Felip E, Mazal J, Manzyuk L, Tan EH, Merimsky O, Sarholz B, Esser R, Gatzemeier U.

Target Oncol. 2015 Jun;10(2):255-65. doi: 10.1007/s11523-014-0336-7. Epub 2014 Sep 9.

PMID:
25195590
17.

Neuroendocrine tumors of the bronchopulmonary system (typical and atypical carcinoid tumors): current strategies in diagnosis and treatment. Conclusions of an expert meeting February 2011 in Weimar, Germany.

Hörsch D, Schmid KW, Anlauf M, Darwiche K, Denecke T, Baum RP, Spitzweg C, Grohé C, Presselt N, Stremmel C, Heigener DF, Serke M, Kegel T, Pavel M, Waller CF, Deppermann KM, Arnold R, Huber RM, Weber MM, Hoffmann H.

Oncol Res Treat. 2014;37(5):266-76. doi: 10.1159/000362430. Epub 2014 Apr 14. Review.

PMID:
24853787
18.

Crizotinib.

Heigener DF, Reck M.

Recent Results Cancer Res. 2014;201:197-205. doi: 10.1007/978-3-642-54490-3_11. Review.

PMID:
24756793
19.

Open, randomized, multi-center phase II study comparing efficacy and tolerability of Erlotinib vs. Carboplatin/Vinorelbin in elderly patients (>70 years of age) with untreated non-small cell lung cancer.

Heigener DF, Deppermann KM, Pawel JV, Fischer JR, Kortsik C, Bohnet S, Eiff MV, Koester W, Thomas M, Schnabel PA, Reck M.

Lung Cancer. 2014 Apr;84(1):62-6. doi: 10.1016/j.lungcan.2014.01.024. Epub 2014 Feb 3.

PMID:
24560332
20.

Management of non-small-cell lung cancer: recent developments.

Reck M, Heigener DF, Mok T, Soria JC, Rabe KF.

Lancet. 2013 Aug 24;382(9893):709-19. doi: 10.1016/S0140-6736(13)61502-0. Review.

PMID:
23972814
21.

Prospective, multicenter, randomized, independent-group, open-label phase II study to investigate the efficacy and safety of three regimens with two doses of sagopilone as second-line therapy in patients with stage IIIB or IV non-small-cell lung cancer.

Heigener DF, von Pawel J, Eschbach C, Brune A, Schmittel A, Schmelter T, Reck M, Fischer JR.

Lung Cancer. 2013 Jun;80(3):319-25. doi: 10.1016/j.lungcan.2013.02.007. Epub 2013 Mar 20.

PMID:
23522488
22.

Topotecan/cisplatin compared with cisplatin/etoposide as first-line treatment for patients with extensive disease small-cell lung cancer: final results of a randomized phase III trial.

Fink TH, Huber RM, Heigener DF, Eschbach C, Waller C, Steinhauer EU, Virchow JC, Eberhardt F, Schweisfurth H, Schroeder M, Ittel T, Hummler S, Banik N, Bogenrieder T, Acker T, Wolf M; “Aktion Bronchialkarzinom” (ABC Study Group).

J Thorac Oncol. 2012 Sep;7(9):1432-9.

23.

The gefitinib long-term responder (LTR)--a cancer stem-like cell story? Insights from molecular analyses of German long-term responders treated in the IRESSA expanded access program (EAP).

Gottschling S, Herpel E, Eberhardt WE, Heigener DF, Fischer JR, Köhne CH, Kortsik C, Kuhnt T, Muley T, Meister M, Bischoff HG, Klein P, Moldenhauer I, Schnabel PA, Thomas M, Penzel R.

Lung Cancer. 2012 Jul;77(1):183-91. doi: 10.1016/j.lungcan.2012.03.003. Epub 2012 Apr 7.

PMID:
22483783
24.

Cross-market cost-effectiveness analysis of erlotinib as first-line maintenance treatment for patients with stable non-small cell lung cancer.

Vergnenègre A, Ray JA, Chouaid C, Grossi F, Bischoff HG, Heigener DF, Walzer S.

Clinicoecon Outcomes Res. 2012;4:31-7. doi: 10.2147/CEOR.S25923. Epub 2012 Jan 26.

25.

Palliative care concepts in respiratory disease.

Heigener DF, Rabe KF.

Respiration. 2011;82(6):483-91. doi: 10.1159/000334189. Epub 2011 Nov 22. Review.

26.

Non-small cell lung cancer in never-smokers: a new disease entity?

Heigener DF.

Onkologie. 2011;34(4):202-7. doi: 10.1159/000326839. Epub 2011 Mar 18. Review.

PMID:
21447981
27.

Second-line erlotinib in patients with advanced non-small-cell lung cancer: subgroup analyses from the TRUST study.

Heigener DF, Wu YL, van Zandwijk N, Mali P, Horwood K, Reck M.

Lung Cancer. 2011 Nov;74(2):274-9. doi: 10.1016/j.lungcan.2011.02.017. Epub 2011 Mar 24.

PMID:
21439671
28.

Mutations in the epidermal growth factor receptor gene in non-small cell lung cancer: Impact on treatment beyond gefitinib and erlotinib.

Heigener DF, Reck M.

Adv Ther. 2011 Feb;28(2):126-33. doi: 10.1007/s12325-010-0096-4. Epub 2010 Dec 16. Review.

PMID:
21181318
29.

Effectiveness of bevacizumab- and pemetrexed-cisplatin treatment for patients with advanced non-squamous non-small cell lung cancer.

Nuijten M, Heigener DF, Bischoff HG, Chouaid C, Vergnenègre A, de Castro Carpeño J, Aultman R, Walzer S, Siebert U.

Lung Cancer. 2010 Aug;69 Suppl 1:S4-10. doi: 10.1016/S0169-5002(10)70132-X. Erratum in: Lung Cancer. 2010 Aug;69 Suppl 1:S31. Lung Cancer. 2010 Nov;70(2):230.

PMID:
20727460
30.

Societal cost savings through bevacizumab-based treatment in non-small cell lung cancer (NSCLC).

Stanisic S, Bischoff HG, Heigener DF, Vergnenègre A, de Castro Carpeño J, Chouaid C, Walzer S, Mueller E, Schmidt E.

Lung Cancer. 2010 Aug;69 Suppl 1:S24-30. doi: 10.1016/S0169-5002(10)70135-5.

PMID:
20727459
31.

Costs of bevacizumab and pemetrexed for advanced non-squamous NSCLC in Italy and Germany.

Bischoff HG, Heigener DF, Walzer S, Nuijten M.

Lung Cancer. 2010 Aug;69 Suppl 1:S18-23. doi: 10.1016/S0169-5002(10)70134-3.

PMID:
20727458
32.

[Palliative care in respiratory medicine].

Magnussen H, Heigener DF, Bausewein C, Thomas M, Eschbach C, Schütte W, Blankenburg T, Steins M, Bischoff H, Schucher B, Rosseau S, Schütz A, Geiseler J, Kampf S, Karg O.

Pneumologie. 2009 May;63(5):289-95. doi: 10.1055/s-0029-1214538. Epub 2009 May 5. Review. German.

34.

[Chemotherapy of malignant pleural mesothelioma: have we made any progress?].

Reck M, Heigener DF, Gatzemeier U.

Zentralbl Chir. 2008 Jun;133(3):238-42. doi: 10.1055/s-2008-1004809. Review. German.

PMID:
18563688
35.

Diagnostics and staging procedures in non-small cell lung cancer - is less more?

Heigener DF, Diemel KD, Reck M, Gatzemeier U.

Clin Respir J. 2008 Apr;2(2):67-73. doi: 10.1111/j.1752-699X.2008.00049.x. Review.

PMID:
20298309
36.

[Non-small cell lung cancer - diagnostics and stage-adapted therapy].

Heigener DF, Reck M, Gatzemeier U.

Med Klin (Munich). 2007 Dec 15;102(12):981-8; quiz 989-90. Review. German.

PMID:
18075718

Supplemental Content

Loading ...
Support Center